Association of Increased Circulating Catecholamine and Glucocorticoid Levels with Risk of Psychological Problems in Oral Neoplasm Patients

Hui Xu1,2,*, Bo Li1,2,*, Li Li3, Xiao-li Zou4, Cai-rong Zhu4, Yi Li1,2, Ning Gao1,2, Qianming Chen1,2, Longjiang Li1,2

1 West China School of Stomatology, Sichuan University, Sichuan Chengdu, China, 2 State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China, 3 Department of medical record management, West China Second University Hospital, Chengdu, China, 4 West China school of Public health, Sichuan University, Chengdu, China

Abstract

Background: Noradrenergic pathways and glucocorticoid-mediated signal pathways have been implicated in the growth and progression of oral cancer. Patients with oral neoplasms can have high psychological distress levels, but the effects of stress-related hormones on oral neoplasm growth are unknown.

Methods: We have investigated the relationships between pre-surgical measurements of psychological problems with Symptom Checklist-90-revised Inventory (SCL90-R), tumor histology, circulating blood catecholamine and glucocorticoid levels among 75 oral neoplasm patients, including 40 oral cancer patients and 35 benign oral tumor patients.

Results: The results showed that most dimension scores of SCL90-R did not show a significant difference between the two groups except depression (p = 0.0201) and obsessive-compulsion (p = 0.0093), with the scores for these symptoms being higher among oral cancer group versus the benign oral tumor group. The differences of total score, average score and other monomial factor scores were not statistically significant. The mean concentrations of catecholamine and glucocorticoid in peripheral blood of the oral cancer group were higher than those in benign oral tumor group (p<0.01). We also examined whether associations observed between biobehavioral measures and circulating blood catecholamine and glucocorticoid levels extended to other compartments in the oral cancer group.

Conclusions: These findings suggest that stress hormones may affect oral cancer behavior by influencing the tumor micro-environment though the circulating blood.

Introduction

A growing number of studies have indicated that the immune alterations resulting from chronic stress and other behavioral conditions may influence cancer development and progression [1–3]. Chronic stress is associated with dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, with consequent increase in the production of the hormone cortisol, and elevated levels of norepinephrine (NE) and epinephrine (E), which are catecholamines released from the adrenal medulla and the neurons of the sympathetic nervous system (SNS) [2,4]. A key component of the stress response involves activation of the sympathetic nervous system (SNS) and production of mediators which arise both from the SNS and the adrenal medulla [5]. Animal-based research has shown that stress can increase levels of intratumoral NE as well as NE in the ovary and other organs that are typical metastatic sites for ovarian cancer such as spleen and omentum [2,6,7].

Patients with oral cancer can have high psychological distress levels, but the effects of stress-related hormones on oral cancer cells and possible mechanisms underlying these relationships are unknown. In one study, the effects of stress-related hormones on interleukin-6 (IL-6) secretion and proliferation of oral squamous cell carcinoma (OSCC) cells was investigated. The effects of NE and cortisol were studied and it was shown that NE and isoproterenol significantly enhanced IL-6 mRNA expression and protein production in SCC9 and SCC25 cells. Physiological stress levels of NE and isoproterenol elicited the most robust IL-6 increase at 1 h. The effects of cortisol varied according to the hormone concentration. These findings suggest that stress hormones can affect oral cancer cell behavior [8].
Noradrenergic pathways have been implicated in the growth and progression of ovarian cancer. Intratumoral NE has been shown to increase with stress in an animal cancer model, but little is known regarding how tumor NE varies with disease stage and with biobehavioral factors in ovarian cancer patients [9]. These results suggest that tumor NE provides distinct information from circulating plasma concentrations. Tumor NE levels were elevated in correlation to tumor grade and stage. Low subjective social support was associated with elevated intratumoral NE. As beta-adrenergic signaling is related to key biological pathways involved in tumor growth, these findings may have implications for patient outcomes in ovarian cancer [9]. In another cancer type, glucocorticoids suppressed androgen-independent prostate cancer growth possibly due to the inhibition of tumor-associated angiogenesis by decreasing VEGF and IL-8 production directly through the glucocorticoid receptor in vivo [7].

Gu et al [10] used two HPLC-MS-MS (High Performance Liquid Chromatography-tandem Mass spectrometry-Mass spectrometry) methods using the Multiple Reaction Monitoring (MRM) acquisition mode for quantitative analysis of 13 compounds in the catecholamine biosynthetic and metabolic pathways. In contrast to other existing methods, the time-consuming sample pretreatment procedure was shortened and even isomeric compounds could be satisfactorily resolved by using the MRM mode. HPLC-MS-MS methods are simple, rapid, reproducible and efficient, and their application might be extended toward other biological samples such as plasma and urine.

In this study, we have evaluated the association between psychological problems and stress-related hormones in primary oral cancer patients. We also examined the relationship between catecholamine levels and tumor stage, which has not been previously characterized. We hypothesized that advanced stage oral cancer would be more associated with higher catecholamine and glucocorticoid levels in circulating blood than worsened psychological problems.

Methods

Ethics statement

This study was conducted according to the guidelines laid down in the Declaration of Helsinki and the Ethics Committee of West China Hospital of Stomatology. Sichuan University approved all procedures involving human subjects and animal studies were conducted in compliance with animal care regulations and applicable national laws (research permit: WCHSIRB-D-2013-054). Written informed consent was obtained from all participants in this study.

Participants

Patients over 18 years of age with a new diagnosis of an oral mass or ulcer suspected to be an oral tumor were recruited. Inclusion was confirmed by histologic diagnosis of primary oral tumor. Patients were excluded for primary cancer of another organ site, oral tumors of systemic disease, use of systemic corticosteroid medication in the previous 6 months, chronic use of beta-blockers, lack of clear histological diagnosis after operation, or comorbidities known to alter the immune response. A total of 75 patients (49 men and 26 women) with oral tumors were included. All tumor samples of included patients were verified by a pathologist. All patients were informed of their diagnosis at the pre-operative conversation. Psychosocial questionnaires were completed during the pre-operative appointment. Blood samples were taken in the pre-surgical waiting area approximately 2 h before surgery, between approximately 9:00 and 11:00 AM.

Biobehavioral, demographic, and medical assessments

Demographic, health behavior, clinical information and histopathologic information was obtained from medical records. Information on demographic characteristics and health behaviors such as hours of sleep, smoking, alcohol and caffeine intake during the 7 days before surgery were provided by patient health reports.

All subjects received the Hopkins Symptom Checklists 90-revised Inventory (SCL90-R), a comprehensive self-assessment survey of 90 questions, which rates a broad range of psychiatric symptoms over the previous 7 days on a 5 point scale, and a demographic questionnaire [11]. In the SCL90-R, subjects responded on a five point scale of distress ranging from “not at all” (0) at one pole to “a little bit” (1), “moderately” (2), “quite a bit” (3) and “extremely” (4) at the other pole [12]. The 90 items of the SCL90-R are grouped along ten symptom dimensions reflecting broad psychological symptom status in a spectrum of individuals. The dimension “psychoticism” (10 items) includes items indicative of a withdrawn, isolated, schizoid lifestyle as well as items representing symptoms of psychosis and schizophrenia such as hallucinations and thought broadcasting. The SCL90-R has shown good internal consistency and test–retest reliability [11]. However, the factor structure of the test has shown inconsistent results. Commonly, less than nine factors are identified, and the psychoticism dimension has been shown to yield the least consistent results [12]. Such inconsistencies have been reported since the very first stages of development of SCL90-R [11]. The SCL90-R inventory measures a broad range of psychological problems and symptoms of psychopathology through three Global Indexes (Global Severity Index, Positive Symptom Distress Index and Positive Symptom Total) and nine primary symptom dimensions comprising a total of 83 items (Somatization, Obsessive–Compulsive, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation and Psychoticism). The Global Severity Index, which is the participant’s mean score (using all 90 items), is a widely used global index of distress.

Measurement of catecholamines and glucocorticoids

Catecholamine levels were determined by high performance liquid chromatography with Mass spectrometry [HPLC-MS-MS]. Plasma samples were collected in chilled EDTA Vacutainer tubes (BD Biosciences, Franklin Lakes, NJ), kept on ice prior to centrifugation, and all samples were stored at −80 °C after collection. Before the sample pretreatment, ascorbic acid was added to the plasma (50 mg/ml) as a stabilizer. Then, 0.1 mL plasma samples were pipetted into a microcentrifuge tube. Acetonitrile (0.1 mL) was added to the sample solution and samples were vortexed for 5 min. After centrifugation at 15000 g for 5 min, the supernatants were introduced into the HPLC-MS-MS system for analysis.

High performance liquid chromatography (HPLC)

Sample analysis was carried out in an Ultimate3000 HPLC system (Dionex). The separation of analytes was performed on a HaloTM C18 column (2.1 x 100 mm, 2.7 μm). The mobile phase was a mixture of methanol-0.01% formic acid (v:v = 90:10). The flow rate was 100 μl/min. The column temperature was set at 25°C.

Mass spectrometry (MS)

Eluants were introduced into a 3200Q TRAP tandem mass spectrometer (Applied Biosystems) operated in electrospray positive mode (ES+) and multiple reaction monitoring (MRM). The capillary voltage was 5.5 kV and the source temperature was
Catecholamines, glucocorticoids and tumor histology

Factor analysis identifying SCL90-R symptom dimensions

Results

Participant characteristics

Table 2 compares the patient characteristics between the oral benign tumor group and the cancer group. There were no significant associations between age or health behaviors. The comparison between the benign tumor group and the cancer group did not show any differences in age, male proportion, tumor location, income, marital status, educational status, distance to the hospital and time to the hospital. There were no significant associations of relationship status (single vs. divorced/separated/widowed vs. married/living with partner) with catecholamine and glucocorticoid levels in any compartment (p>0.34).

Factor analysis identifying SCL90-R symptom dimensions

Most dimension scores of SCL90-R did not show a significant difference between the benign tumor and cancer patient groups except depression (p = 0.0201) and obsessive-compulsion (p = 0.0093). There were no significant associations of relationship status with somatization (p = 0.1111), interpersonal sensitivity (p = 0.1938), anxiety (p = 0.0962), hostility (p = 0.6099), phobic anxiety (p = 0.5066), and paranoid ideation (p = 0.2734), or psychosis (p = 0.3571) between the two groups (Table 3).

Catecholamines, glucocorticoids and tumor histology

The HPLC-MS-MS method provides better specificity for analysis in comparison to LC-MS, since it monitors ion transitions using MRM. The ions selected for the identification of each analyte were not always the most abundant but were the most specific ones. Representative extracted ion chromatograms and mass spectrum of standard mixture for each compound are depicted in Fig. 1 and 2, respectively.

The mean concentrations of catecholamines in peripheral blood in the oral cancer group were higher than those in oral benign tumor group. The concentrations of catecholamines in peripheral blood were 70.27±34.50 pg/ml (epinephrine) and 316.73±109.22 pg/ml (norepinephrine) in oral cancer group, versus 49.48±31.04 pg/ml (epinephrine) and 252.14±81.80 pg/ml (norepinephrine) in the oral benign tumor group, with the differences between the two groups being statistically significant (all P<0.01). The mean concentrations of glucocorticoids in peripheral blood in the oral cancer group were also higher than those in the oral benign tumor group. In the oral cancer group, the concentrations of glucocorticoids in peripheral blood were 20.21±7.11 ng/ml (cortisone) and 119.89±44.13 pg/ml (hydrocortisone) in the oral cancer group, versus 8.96±3.09 ng/ml (epinephrine) and 70.44±24.91 ng/ml (hydrocortisone) in oral benign tumor group, with these differences between the two groups also being statistically significant (all P<0.001; Table 4).

Peripheral blood catecholamines and glucocorticoid levels differed substantially as a function of cancer stage, with Stage I and II (early stage) cancer showing comparatively low concentrations (epinephrine 56.61±23.09 pg/ml, norepinephrine 267.81±89.77 pg/ml, cortisol 18.55±6.48 ng/ml, and hydrocortisone 106.95±46.71 ng/ml), and Stage III and IV (advanced stage) cancer showing substantially greater concentrations (epinephrine 88.75±39.20 pg/ml, norepinephrine 382.91±99.50 pg/ml, cortisol 22.44±7.51 ng/ml, hydrocortisone 137.40±34.54 ng/ml) as shown in Figure 3, Table 5. In each case, except for cortisol, the contrast between advanced-stage and early-stage cancer in these measurements was highly significant (Table 5).

Biobehavioral factors and catecholamines in three compartments

To better understand the contributions of catecholamines and glucocorticoids in the process of tumorigenesis among patients, we further analyzed possible interactions between these substances and patient mental health characteristics. Patients with depression and/or obsessive-compulsive psychological problems typically had significantly higher catecholamine and glucocorticoid levels in the oral cancer group versus the oral benign group, and levels in the advanced stage cancers were significantly higher than in early-stage cancers.

As shown in Fig. 4, patients with higher levels of obsessive-compulsive psychological problems had higher peripheral blood catecholamines and glucocorticoids (βHSE = 31.364, PNE = 0.039;


Table 2. Patient characteristics.

| Characteristics          | Benign Group (N = 35) | Cancer Patients Group (N = 40) | t      | χ² | P     |
|--------------------------|-----------------------|-------------------------------|--------|----|-------|
| Basics                   |                       |                               |        |    |       |
| Age (mean ± Sd)          | 44.37±14.57           | 50.7±12.39                    | 2.03   | -  | 0.056 |
| Age (range)              | (18, 74)              | (27, 78)                      | -      | -  | -     |
| Male %                   | 21 (60.0%)            | 28 (70.0%)                    | -      | 0.82| 0.364 |
| Income (RMB¥), %         |                       |                               |        |    |       |
| <1000                    | 7 (20.0%)             | 8 (20.0%)                     | -      | 1.08| 0.993 |
| [1000, 2000]             | 8 (22.9%)             | 10 (25.0%)                    | -      | -  | -     |
| [2000, 4000]             | 14 (40.0%)            | 14 (35.0%)                    | -      | -  | -     |
| [4000, 6000]             | 6 (17.1%)             | 7 (17.5%)                     | -      | -  | -     |
| ≥6000                    | 0 (0%)                | 1 (2.5%)                      | -      | -  | -     |
| Marital Status, %        |                       |                               |        |    |       |
| Single                   | 5 (14.3%)             | 1 (2.5%)                      | -      | 3.84| 0.251 |
| Married/living with partner | 27 (77.1%)   | 33 (82.5%)                    | -      | -  | -     |
| Divorced/separated       | 2 (5.7%)              | 4 (10.0%)                     | -      | 1.08| 0.993 |
| Widowed                  | 1 (2.9%)              | 2 (5.0%)                      | -      | -  | -     |
| Educational Background, %|                       |                               |        |    |       |
| Under a high school education | 6 (17.1%)        | 12 (30.0%)                    | -      | 4.38| 0.345 |
| Senior High School education | 9 (25.7%)         | 9 (22.5%)                     | -      | -  | -     |
| University degree        | 19 (54.3%)            | 19 (47.5%)                    | -      | -  | -     |
| Master degree or above   | 1 (2.9%)              | 0 (0%)                        | -      | -  | -     |
| Accessibility            |                       |                               |        |    |       |
| Distance to the hospital (Km) | 131.94±156.61        | 171.35±280.20 (M = 70.0)     | -0.18  | -  | 0.861 |
| Time to the hospital (Hr) | 3.17±2.68 (M = 2.0)  | 3.31±3.39 (M = 2.0)          | -0.37  | -  | 0.710 |
| Grade                    |                       |                               |        |    |       |
| I                        | -                     | 9 (22.5%)                     | -      | -  | -     |
| II                       |                       | 18 (45.0%)                    | -      | -  | -     |
| III                      |                       | 13 (32.5%)                    | -      | -  | -     |
| Stage                    |                       |                               |        |    |       |
| 1                        | -                     | 4 (10.0%)                     | -      | -  | -     |
| 2                        | -                     | 19 (47.5%)                    | -      | -  | -     |
| 3                        | -                     | 10 (25.0%)                    | -      | -  | -     |
| 4                        | -                     | 7 (17.5%)                     | -      | -  | -     |
| Scale Score              |                       |                               |        |    |       |
| SCL-90(Global Severity Index) | 132.46±27.80         | 143.15±25.12                 | 1.75   | -  | 0.084 |

doi:10.1371/journal.pone.0099179.t002

\[ \beta^E = 115.783, \ P^E = 0.007; \ \beta^\text{cortisone} = 4.165, \ P^\text{cortisone} = 0.071; \ \beta^\text{hydrocortisone} = 28.165, \ P^\text{hydrocortisone} = 0.044 \]. We also examined whether the relationships between depression and/or obsessive-compulsive psychological problems and cancer stage would be reflected in the peripheral blood catecholamine and glucocorticoid levels. As with the relation to cancer stage, a similar trend was seen for psychological problems in relation to peripheral blood catecholamines and glucocorticoids.

Discussion

Clinical and epidemiological studies have demonstrated positive associations between stress and cancer progression. A key component of the stress response involves the locus ceruleus/norepinephrine (LC/NE) sympathetic system and production of mediators such as NE and E, which arise both from the sympathetic system and the adrenal medulla, suggesting that tumor NE provides distinct information from circulating plasma concentrations [7]. It has been proven that tumors in stressed animals show markedly increased vascularization and enhanced expression of VEGF, MMP2 and MMP9[2]. These data identify β-adrenergic activation as a major mechanism by which behavioral stress can enhance tumor angiogenesis in vivo and thereby promote malignant cell growth. These data also suggest that blocking ADRB (Adrenergic Receptor β)-mediated angiogenesis could have therapeutic implications for the management of ovarian cancer. It was recently shown that both NE and E levels are elevated in a sustained fashion in ovarian and other peritoneal tissues in preclinical models of chronic stress [2]. These hormonal increases were related to greater tumor burden, which was mediated by increased angiogenesis [2].
The other major neuroendocrine response to stress is via activation of the HPA axis, consisting of consequent release of the neuropeptides corticotrophin releasing hormone and vasopressin, which stimulate pituitary adrenocorticotropic hormone (ACTH) release. This leads to stimulation of glucocorticoid secretion by the adrenal cortex, which is essential for stress adaptation [13,14].

Mice undergoing stress show rises in endogenous glucocorticoid levels [15], suggesting that glucocorticoids are involved in stress induced thymic-involuton [16]. Plasma glucocorticoid levels in tumor-bearing animals were similar to that of normal mice [17].

A growing number of studies have shown that hormonal and immune alterations resulting from chronic stress and other

| SCL-90    | Benign Group (N = 35) | Cancer Patients Group (N = 40) | Z  | P       |
|-----------|----------------------|-------------------------------|----|---------|
|           | Mean ± SD            | Mean ± SD                     |    |         |
| somatization | 1.52 ± 0.49         | 1.60 ± 0.38                   | −1.59 | 0.1111 |
| obsessive-compulsion | 1.57 ± 0.40         | 1.82 ± 0.38                   | −2.60 | 0.0093 |
| sensitive | 1.44 ± 0.39          | 1.54 ± 0.35                   | −1.48 | 0.1398 |
| depression | 1.42 ± 0.32          | 1.57 ± 0.31                   | −2.32 | 0.0201 |
| anxiety   | 1.45 ± 0.30          | 1.58 ± 0.36                   | −1.66 | 0.0962 |
| hostility | 1.62 ± 0.60          | 1.62 ± 0.44                   | −0.51 | 0.6099 |
| phobic anxiety | 1.43 ± 0.42         | 1.47 ± 0.37                   | −0.66 | 0.5066 |
| paranoid ideation | 1.47 ± 0.37         | 1.54 ± 0.34                   | −1.10 | 0.2734 |
| psychosis | 1.42 ± 0.34          | 1.46 ± 0.30                   | −0.92 | 0.3571 |

doI:10.1371/journal.pone.0099179.t003

Figure 1. Chromatograms of Adrenaline, Noradrenaline, Cortisone and hydrocortisone.
doI:10.1371/journal.pone.0099179.g001
behavioral conditions may influence cancer development and progression [8]. Chronic stress is associated with dysregulation of the HPA axis and the LC/NE sympathetic system, with a consequent increase in the production of the hormone cortisol and elevated levels of NE and E. Catecholamines were released from the adrenal medulla and the neurons of LC/NE sympathetic system to promote tumor growth and angiogenesis [9].

The key findings of this study are that peripheral blood catecholamine and glucocorticoid levels in primary oral cancer patients are linked to both disease severity and patient psychosocial characteristics. Catecholamines and glucocorticoids were elevated in patients with advanced stage disease and higher grade pathology. Symptoms of mental illness were related to plasma catecholamines. Shahzad demonstrated that behavioral stress increases intratumoral NE in an orthotopic mouse model of ovarian cancer [6]. Also, increases in NE in organs that are typical metastatic sites for ovarian cancer have been reported [2]. Sook et al. found that the intratumoral catecholamine differences observed affect biological pathways involved in tumor progression such as angiogenesis, invasion, anoikis, transcription pathway activation, etc [18]. Others have shown a possible link between psychosocial distress and increased risk of metastasis [2].

In our study, a higher global severity index was associated with increased psychiatric distress between two groups than Chinese norms. However, the difference between the two groups was not significant. Indeed, our data and those of others suggest that patients diagnosed with oral cancer have more emotional distress than patients diagnosed with oral benign tumors. We observed similar global distress severity among the groups of patients. In the whole study, patients with lower scores on the SCL90R scale were at lower stage than those with higher scores. These findings provide support for linking depression and obsessive-compulsion with oral cancer. However, our data partially support that the circulating levels of catecholamine may be related to cancer stage. Greater psychological problems were not associated with higher catecholamine and glucocorticoid levels in circulating blood versus tumor tissue.

In comparison to other studies, we found high rates of psychotic symptoms in the two groups. Lutgendorf reported elevated tumor catecholamines accompanying biobehavioral risk factors in a small sample of human ovarian cancer patients [19]. It was also reported

Table 4. Comparison catecholamine and glucocorticoid concentrations between oral cancer and benign oral tumor patients.

| Blood index            | Benign Group (N = 35) | Cancer Patients Group (N = 40) | t    | Z    | p    |
|------------------------|-----------------------|--------------------------------|------|------|------|
|                        | Mean± Sd              | Mean± Sd                       |      |      |      |
| Plasma epinephrine (pg/ml) | 49.48±31.04           | 70.27±34.50                    | -    | -2.97| 0.0030|
| Plasma norepinephrine (pg/ml) | 252.14±81.80         | 316.73±109.22                  | -    | -2.89| 0.0039|
| Plasma cortisone (ng/ml)   | 8.96±3.09             | 20.21±7.11                     | 9.07 | -    | <.0001|
| Plasma hydrocortisone (ng/ml) | 70.44±24.91          | 119.89±44.13                   | 6.07 | -    | <.0001|

Figure 2. Mass Spectrum of Adrenaline, Noradrenaline, Cortisone and hydrocortisone.
doi:10.1371/journal.pone.0099179.g002
that tumor NE provides distinct information from circulating plasma concentrations. Tumor NE levels were elevated in accordance with tumor grade and stage. Low subjective social support was associated with elevated intratumoral NE [9]. We found advanced stage oral cancer to be associated with higher catecholamine and glucocorticoid levels in peripheral blood, and our data suggest that those substances affect the tumor microenvironment though the circulating blood rather than the tumor matrix. These findings supported our hypothesis that oral cancer patients would have high levels of peripheral blood catechol-

Table 5. Peripheral blood catecholamine and glucocorticoid levels differed with cancer stage.

| Variable     | Stage   | N   | Mean  | Std Dev | t    | p     |
|--------------|---------|-----|-------|---------|------|-------|
| epinephrine  | early   | 23  | 56.60 | 23.09   | −3.02| 0.006 |
| epinephrine  | advanced| 17  | 88.75 | 39.20   |      |       |
| Norepinephrine| early  | 23  | 267.81| 89.77   | −3.83| 0.0005|
| Norepinephrine| advanced| 17 | 382.91| 99.50   |      |       |
| Cortisone    | early   | 23  | 18.55 | 6.47    | −1.76| 0.0868|
| Cortisone    | advanced| 17  | 22.44 | 7.51    |      |       |
| Hydrocortisone| early  | 23  | 106.95| 46.71   | −2.27| 0.029 |
| Hydrocortisone| advanced| 17 | 137.40| 34.34   |      |       |

doi:10.1371/journal.pone.0099179.t005

Figure 3. Peripheral blood catecholamines and glucocorticoids levels differed substantially as a function of cancer stage.
doi:10.1371/journal.pone.0099179.g003
amines, whereas oral benign tumor patients would have lower levels. Contrary to our hypothesis, both groups of patients were associated with high levels of psychological problems such as obsessive-compulsion and depression.

The present study has several limitations. First, we did not control for the fact that different surgeries might have affected the patient’s cognitive ability. Further studies including the assessment of objective cognitive impairment will be needed to determine the effect of differences in surgical procedures. Also, this study did not provide practical implications of subjective symptoms. Thus, additional research is necessary to confirm the relationship between subjective symptoms and difficulties in daily lives of individuals with oral cancer.

Acknowledgments
We would like to thank Dr. James J. Cody from University of Alabama at Birmingham for his kind help in the manuscript preparation.

Author Contributions
Conceived and designed the experiments: HXX LJL. Performed the experiments: BL LL HXX. Analyzed the data: BL LL CRZ HXX. Contributed reagents/materials/analysis tools: XLZ HXX LL. Wrote the paper: BL HXX QMC LJL YL NG.

References
1. Reiche EM, Nunes SO, Morimoto HK, Reiche EMV, Nunes SOV (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5: 617–625.
2. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, et al (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12: 939–944.
3. Antoni MH, Lehman JM, Kilbourn KM, Boyers AE, Culver JL, et al (2001) Cognitive-Behavioral Stress Management Intervention Decreases the Prevalence of Depression and Enhances Benefit Finding Among Women Under Treatment for Early-Stage Breast Cancer. Health Psychol 20: 20–32.
4. Kiecolt JK, Stephens RE, Lipetz PD, Speicher GE, Glaser R (1990) Distress and DNA repair in human lymphocytes. J Behav Med 3: 311–320.
5. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87: 873–904.
6. Shahzad MR, Arevalo JM, Armaiz GN, Lu C, Stone RL, et al (2010) Stress effects on FoxP3 and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 285: 35462–35470.
7. Yano A, Fujiy Y, Iwai A, Kageyama Y, Kihara K, et al (2006) Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12: 3003–3009.
8. Bernabe DG, Tamae AC, Biasoli ER, Oliveira SH, Bernabe DG, et al (2011) Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain Behav Immun 25: 574–583.
9. Latendord SK, DeGeest K, Dahmoush L, Farley D, Penedo F, et al (2011) Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 25: 250–5.
10. Gu Q, Shi X, Yin P, Gao P, Lu X, et al (2008) Analysis of catecholamines and their metabolites in adrenal gland by liquid chromatography tandem mass spectrometry. Anal Chim Acta 609: 192–200.
11. Derogatis LR (1977) Factorial invariance across gender for the primary symptom dimensions of the SCL-90. Br J Soc Clin Psychol 16: 347–36.
12. Olsen CA, Ghadiri MR (2009) Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides. J Med Chem 52: 7836–7846.

13. Aguilera G (2011) HPA axis responsiveness to stress: implications for healthy aging. Exp Gerontol 46: 90–95.

14. Aguilera G (1994) Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrin 15: 321–350.

15. Taric N, Ovadia H, Weiss DW, Weidenfeld J (1998) Restraint stress-induced thymic involution and cell apoptosis are dependent on endogenous glucocorticoids. J Neuroimmunol 82: 40–46.

16. Sapolsky RM, Romero LM, Munck AU (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21: 55–89.

17. Biswas R, Roy T, Chattopadhyay U, Biswas R, Roy T, et al (2006) Prolactin induced reversal of glucocorticoid mediated apoptosis of immature cortical thymocytes is abrogated by induction of tumor. J Neuroimmunol 171: 120–134.

18. Sood AK, Armaiz GN, Haldar J, Nick AM, Stone RL, et al (2010) Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120: 1515–1523.

19. Lutgendorf SK, DeGeest K, Sung CY, Arevalo JM, Penedo F, et al (2009) Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun 23: 176–183.